The DOI matches its Crossref record.
Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, older subjects appear to be at increased risk of isoniazid and amoxicillin‐clavulanate hepatotoxicity, whereas younger individuals are more prone to develop DILI from anticonvulsants and minocycline.45,46”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- Randolph, 1953, Toxic hepatitis with jaundice occurring in a patient treated with isoniazid, JAMA, 152, 38, 10.1001/jama.1953.63690010014007i · DOI
- Cohen, 1961, Total hepatic necrosis secondary to isoniazid therapy, JAMA, 176, 877, 10.1001/jama.1961.63040230013013b · DOI
- Black, 1975, Isoniazid-associated hepatitis in 114 patients, Gastroenterology, 69, 289, 10.1016/S0016-5085(19)32568-5 · DOI · Paper page
- Kopanoff, 1978, Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study, Am Rev Respir Dis, 117, 991
- Riska, 1979, Hepatitis cases in isoniazid treated groups and in a control group, Bull Int Union Tuberc, 54, 65
- Moulding, 1989, Twenty isoniazid-associated deaths in one state, Am Rev Respir Dis, 140, 700, 10.1164/ajrccm/140.3.700 · DOI
- Franks, 1989, Isoniazid hepatitis among pregnant and postpartum Hispanic patients, Public Health Rep, 104, 151
- Snider, 1992, Isoniazid-associated hepatitis deaths, Am Rev Respir Dis, 145, 494, 10.1164/ajrccm/145.2_Pt_1.494 · DOI
- Millard, 1996, Isoniazid-related fatal hepatitis, West J Med, 164, 486
- Nolan, 1999, Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a Public Health Tuberculosis Clinic, JAMA, 281, 1014, 10.1001/jama.281.11.1014 · DOI · Paper page
- ATS/CDC/IDSA joint statement, 2003, Treatment of tuberculosis, Am J Respir Crit Care Med, 167, 603, 10.1164/rccm.167.4.603 · DOI
- LoBue, 2003, Use of isoniazid for latent tuberculosis infection in a public health clinic, Am J Respir Crit Care Med, 168, 443, 10.1164/rccm.200303-390OC · DOI
- Jasmer, 2002, Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial, Ann Intern Med, 137, 640, 10.7326/0003-4819-137-8-200210150-00007 · DOI
- McNeill, 2003, Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis, Chest, 123, 102, 10.1378/chest.123.1.102 · DOI
- Jasmer, 2000, Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis, Am J Respir Crit Care Med, 162, 1648, 10.1164/ajrccm.162.5.2003028 · DOI
- Gordin, 2000, Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV infected persons, JAMA, 283, 1445, 10.1001/jama.283.11.1445 · DOI
- Centers for Disease Control and Prevention, 2003, Update adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent tuberculosis infection, MMWR Morb Mortal Wkly Rep, 52, 735
- Peretti, 1987, Acetylating of acetylhydrazine, the toxic metabolite of isoniazid, in humans: inhibition by concomitant administration of isoniazid, J Pharmacol Exp Ther, 243, 686
- Yue, 2004, CYP2E1 mediated isoniazid-induced hepatotoxicity in rats, Acta Pharmacol Sin, 25, 699
- Official Statement of the American Thoracic Society, 2000, Targeted tuberculin testing and treatment of latent tuberculosis infection, Am J Respir Crit Care Med, 161, 5221
- Byrd, 1977, Isoniazid chemoprophylaxis: association with detection and incidence of liver toxicity, Arch Intern Med, 137, 1130, 10.1001/archinte.1977.03630210016007 · DOI
- Scharer, 1969, Serum transaminase elevations and their hepatic abnormalities in patients receiving isoniazid, Ann Intern Med, 71, 1113, 10.7326/0003-4819-71-6-1113 · DOI
- Bailey, 1973, Disturbed hepatic function during isoniazid chemprophylaxis, Am Rev Respir Dis, 107, 523, 10.1164/arrd.1973.107.4.523 · DOI
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Metadata
- Authors
- Fountain, F. F., Tolley, E., Chrisman, C. R., & Self, T. H.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 128
- Issue
- 1
- Pages
- 116-123
- ISSN
- 0012-3692
- Cited by
- 209
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection. https://app.cochat.ai/papers/10.1378/chest.128.1.116
- The paper
- Fountain, F. F., Tolley, E., Chrisman, C. R., & Self, T. H. (2005). Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection. Chest. https://doi.org/10.1378/chest.128.1.116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
